Further indications

SIR-Spheres® Y-90 resin microspheres are approved and indicated in over 40 countries for the treatment of patients with inoperable liver tumours. In additon to its use in metastatic Colorectal Cancer and Hepatocellular Carcinoma, a broad range of clinical experience has been gained in patients with liver metastases from Neuroendocrine Tumours, Breast Cancer, Ocular Melanoma and Pancreatic Cancer, and in Cholangiocarcinoma.

In addition, several studies are currently investigating the effect of SIR-Spheres Y-90 resin microspheres on tumours that have spread to the liver from Ocular Melanoma, Breast Cancer and Cholangiocarcinoma.

Sirtex is broadening its focus to examine the use of SIR-Spheres Y-90 resin microspheres in a number of cancers outside the liver. The first of these studies, RESIRT, is investigating its potential benefit in the treatment of primary Renal Cell Cancer.



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage